In an unparalleled moment of technological advancement, as the growing prowess of AI becomes unignorable and researchers break new barriers every week in the treatment of cancer, Alzheimer’
As the healthcare industry emerges at last from the COVID-19 pandemic into a new, digitally supercharged world, stakeholders across the industry must move fast to embrace digital transforma
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh